Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) reported positive results from a Phase 3 study of fostamatinib to treat adult chronic/persistent immune thrombocytopenia sending the stock price soaring $1.29 to close at $3.93.
Positive study results for Rigel Pharmaceuticals
August 30, 2016 at 18:35 PM EDT